Related Experiment Videos
Phase II trial of amsacrine in patients with multiple myeloma
P R Greipp1, M Coleman, K Anderson
1Mayo Clinic, Rochester, Minnesota.
Medical and Pediatric Oncology
|January 1, 1989
Abstract:
Seventy-four previously treated patients with multiple myeloma were treated with Amsacrine (m-AMSA) 120 mg/m2 every 3 weeks. A good response was observed in two patients (3%), and improvement was seen in three patients (4%). Severe toxicity was observed in 33% of patients who received three or more courses of treatment. This dose and schedule of m-AMSA in multiple myeloma is usually ineffective.